What's in Universidad de Granada's pipeline?

Universidad de Granada has 6 drugs in our index: 3 marketed, 0 filed, 0 in Phase 3, 0 in Phase 2, 3 in Phase 1.

Which companies overlap with Universidad de Granada's portfolio?

No competitive overlap detected.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/universidad-de-granada.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Universidad de Granada — Portfolio Competitive Intelligence Brief

Universidad de Granada pipeline: 3 marketed, 0 filed, 0 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 0 Phase 3 0 Phase 2 3 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
GTO®	GTO®	marketed			Other
trazodone, pregabalin	trazodone, pregabalin	marketed	Combination anxiolytic/analgesic (serotonin antagonist and reuptake inhibitor + gabapentinoid)	5-HT2A receptor, serotonin transporter (SERT), alpha-2-delta calcium channel subunit	Psychiatry/Neurology (Anxiety, Pain Management)
Hydroxypropyl Guar	Hydroxypropyl Guar	marketed

Therapeutic area mix

Other · 2
Psychiatry/Neurology (Anxiety, Pain Management) · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

No competitive overlap data.

Subscribe to ongoing alerts

Every new pipeline event for Universidad de Granada:

Cite this brief

Drug Landscape (2026). Universidad de Granada — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/universidad-de-granada. Accessed 2026-05-16.